Colon Cancer Treatment Regimens

Share this content:

SEE BELOW THE CHART TO SEE GASTROINTESTINAL CANCER DRUG MONOGRAPHS.

COLON CANCER TREATMENT REGIMENS

Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment.

Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies.

These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

Systemic Therapy for Advanced or Metastatic Disease - Chemotherapy Regimens1

NOTE: All recommendations are category 2A unless otherwise indicated.

REGIMEN

DOSING

mFOLFOX62-4,a

Day 1: Oxaliplatin 85mg/m2 IV over 2 hours

Day 1: Leucovorin 400mg/m2 IV over 2 hours

Days 12: 5-FU 400mg/m2 IV bolus on day 1, then 1,200mg/m2/day × 2 days (total 2,400mg/m2 over 46–48 hours) IV continuous infusion.

Repeat cycle every 2 weeks.

mFOLFOX75,a

Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV followed by

Days 12: 5-FU 1,200mg/m2/day (total 2,400mg/m2 over 46-48 hours) IV continuous infusion.

Repeat every 2 weeks.

FOLFOX + bevacizumab6

Day 1: Oxaliplatin 85mg/m2 IV over 2 hours

Day 1: Leucovorin 400mg/m2 IV over 2 hours

Days 12: 5-FU 400mg/m2 IV bolus on day 1, then 1,200mg/m2/day × 2 days (total 2,400mg/m2 over 46–48 hours) IV continuous infusion

Day 1: Bevacizumab 5mg/kg IV.

Repeat cycle every 2 weeks.

FOLFOX + panitumumab (KRAS/NRAS WT gene only)7

Day 1: Oxaliplatin 85mg/m2 IV over 2 hours

Day 1: Leucovorin 400mg/m2 IV over 2 hours

Days 12: 5-FU 400mg/m2 IV bolus on day 1, then 1,200mg/m2/day × 2 days (total 2,400mg/m2 over 46–48 hours) IV continuous infusion

Day 1: Panitumumab 6mg/kg IV over 60 minutes.

Repeat cycle every 2 weeks.

FOLFOX + cetuximab (KRAS/NRAS WT gene only)8

Day 1: Oxaliplatin 85mg/m2 IV over 2 hours

Day 1: Leucovorin 400mg/m2 IV over 2 hours

Days 1–3: 5-FU 400mg/m2 IV bolus on day 1, then 1,200mg/m2/day × 2 days (total 2,400mg/m2 over 46–48 hours) IV continuous infusion.

Repeat cycle every 2 weeks, plus

Cetuximab 400mg/m2 IV over 2 hours for the first infusion, then 250mg/m2 IV over 60 minutes weekly.

OR

Day 1: Cetuximab 500mg/m2 IV over 2 hours every 2 weeks.

CapeOX9,b

Day 1: Oxaliplatin 130mg/m2 IV over 2 hours

Days 1–14: Capecitabine 850–1,000mg/m2 orally twice daily.

Repeat cycle every 3 weeks.

CapeOX + bevacizumab9

Day 1: Oxaliplatin 130mg/m2 IV over 2 hours

Days 1–14: Capecitabine 850–1,000mg/m2 orally twice daily

Day 1: Bevacizumab 7.5mg/kg IV.

Repeat cycle every 3 weeks.

FOLFIRI10,11,a

Day 1: Irinotecan 180mg/m2 IV over 30–90 minutes

Day 1: Leucovorin 400mg/m2 IV infusion to match duration of irinotecan infusion

Days 12: 5-FU 400mg/m2 IV bolus day 1, then 1,200mg/m2/day × 2 days (total 2,400mg/m2 over 46–48 hours) continuous infusion.

Repeat cycle every 2 weeks.

FOLFIRI + bevacizumab12

Day 1: Irinotecan 180mg/m2 IV over 30–90 minutes

Day 1: Leucovorin 400mg/m2 IV infusion to match duration of irinotecan infusion

Days 12: 5-FU 400mg/m2 IV bolus day 1, then 1,200mg/m2/day × 2 days (total 2,400mg/m2 over 46–48 hours) IV continuous infusion

Day 1: Bevacizumab 5mg/kg IV.

Repeat cycle every 2 weeks.

FOLFIRI + cetuximab (KRAS/NRAS WT gene only)13,14

Day 1: Irinotecan 180mg/m2 IV over 30–90 minutes

Day 1: Leucovorin 400mg/m2 IV infusion to match duration of irinotecan infusion

Days 12: 5-FU 400mg/m2 IV bolus day 1, then 1,200mg/m2/day × 2 days (total 2,400mg/m2 over 46–48 hours) IV continuous infusion, plus

Days 1 and 8: Cetuximab 400mg/m2 IV over 2 hours first infusion, then 250mg/m2 IV over 60 minutes.

or

Day 1: Cetuximab 500mg/m2 IV over 2 hours.

Repeat cycle every 2 weeks.

FOLFIRI + panitumumab (KRAS/NRAS WT gene only)15

Day 1: Irinotecan 180mg/m2 IV over 30–90 minutes

Day 1: Leucovorin 400mg/m2 IV infusion to match duration of irinotecan infusion

Days 12: 5-FU 400mg/m2 IV bolus day 1, then 1,200mg/m2/day × 2 days (total 2,400mg/m2 over 46–48 hours) IV continuous infusion

Day 1: Panitumumab 6mg/kg IV over 60 minutes.

Repeat cycle every 2 weeks.

FOLFIRI + ziv-aflibercept16

Day 1: Irinotecan 180mg/m2 IV over 30–90 minutes

Day 1: Leucovorin 400mg/m2 IV infusion to match duration of irinotecan infusion

Days 1–2: 5-FU 400mg/m2 IV bolus day 1, then 1,200mg/m2/day × 2 days (total 2,400mg/m2 over 46–48 hours) continuous infusion

Day 1: Ziv-aflibercept 4mg/kg IV over 1 hour.

Repeat cycle every 2 weeks.

FOLFIRI + ramucirumab17

Day 1: Irinotecan 180mg/m2 IV over 30–90 minutes

Day 1: Leucovorin 400mg/m2 IV infusion to match duration of irinotecan infusion

Days 1–2: 5-FU 400mg/m2 IV bolus day 1, then 1,200mg/m2/day × 2 day (total 2,400mg/m2 over 46–48 hours) IV continuous infusion

Day 1: Ramucirumab 8mg/kg IV over 60 minutes.

Repeat cycle every 2 weeks.

FOLFOXIRI18,a

Day 1: Irinotecan 165mg/m2 over 30 to 90 minutes + oxaliplatin 85mg/m2 over 2 hours

Day 1: Leucovorin 400mg/m2 over 2 hours

Days 1-2: Fluorouracil 1,200mg/m2 (2,400mg/m2 over 48 hours) IV continuous infusion.

Repeat cycle every 2 weeks.

FOLFOXIRI + bevacizumab19

Day 1: Irinotecan 165mg/m2 IV + oxaliplatin 85mg/m2 IV

Day 1: Leucovorin 400mg/m2 IV

Days 1–3: Fluorouracil 1,600mg/m2/day × 2 days (total 3,200mg/m2 over 48 hours) continuous infusion starting on day 1, ±

Day 1: Bevacizumab 5mg/kg IV.

Repeat cycle every 2 weeks.

IROX20

Day 1: Oxaliplatin 85mg/m2 IV over 2 hours, followed by irinotecan 200mg/m2 IV over 30–90 minutes.

Repeat cycle every 3 weeks.

Bolus or infusional 5-FU/leucovorin Roswell Park regimen21

Days 1, 8, 15, 22, 29, and 36: Leucovorin 500mg/m2 IV over 2 hours

Days 1, 8, 15, 22, 29, and 36: 5-FU 500mg/m2 IV bolus 1 hour after start of leucovorin.

Repeat cycle every 8 weeks.

Simplified biweekly infusional 5-FU/LV (sLV5FU2)10,a

Day 1: Leucovorin 400mg/m2 IV over 2 hours

Days 1–3: 5-FU bolus 400mg/m2 and then 1,200mg/m2/day × 2 days (total 2,400mg/m2 over 46–48 hours) continuous infusion.

Repeat cycle every 2 weeks.

Weekly infusional LV5FU222

Day 1: Leucovorin 20mg/m2 IV over 2 hours

Day 1: 5-FU 500mg/m2 IV bolus injection 1 hour after the start of leucovorin.

Repeat cycle every week

OR

Day 1: 5-FU 2,600mg/m2 by 24-hour infusion plus leucovorin 500mg/m2 IV.

Repeat cycle every week.

Capecitabine9

Days 1–14: Capecitabine 850–1,250mg/m2 orally twice daily.

Repeat cycle every 3 weeks.

Capecitabine + bevacizumab23

Day 1: Bevacizumab 7.5mg/kg IV

Days 1–14: Capecitabine 850–1,250mg/m2 orally twice daily.

Repeat cycle every 3 weeks.

Irinotecan24,25

Days 1 and 8: Irinotecan 125mg/m2 IV over 30–90 minutes.

Repeat cycle every 3 weeks.

OR

Day 1: Irinotecan 300–350mg/m2 IV over 30–90 minutes.

Repeat cycle every 3 weeks.

OR

Day 1: Irinotecan 180mg/m2 IV over 30–90 minutes.

Repeat cycle every 2 weeks.

Cetuximab (KRAS/NRAS WT gene only) + irinotecan14,26

Cetuximab 400mg/m2 first infusion, then 250mg/m2 IV weekly OR cetuximab 500mg/m2 IV every 2 weeks, +

Irinotecan 300–350mg/m2 IV every 3 weeks OR irinotecan 180mg/m2 IV every 2 weeks OR irinotecan 125mg/m2 on days 1 and 8 and repeat every 3 weeks.

Irinotecan + cetuximab + vemurafenib (BRAF V600E mutation positive)27

Day 1: Irinotecan 180mg/m2 IV over 30-90 minutes + cetuximab 500mg/m2 IV

Days 1-14: Vemurafenib 960mg orally twice daily.

Repeat cycle every 2 weeks.

Irinotecan + panitumumab + vemurafenib (BRAF V600E mutation positive)1

Day 1: Irinotecan 180mg/m2 IV over 30-90 minutes + panitumumab 6mg/kg IV over 60 minutes

Days 1-14: Vemurafenib 960mg orally twice daily.

Repeat cycle every 2 weeks.

Cetuximab (KRAS/NRAS WT gene only)14,26

Day 1: Cetuximab 400mg/m2 first infusion, then 250mg/m2 IV weekly

OR

Day 1: Cetuximab 500mg/m2 IV over 2 hours every 2 weeks

Repeat cycle every 2 weeks.

Panitumumab (KRAS/NRAS WT gene only)28

Day 1: Panitumumab 6mg/kg IV over 60 minutes.

Repeat cycle every 2 weeks.

Regorafenib29,30

Days 1–21: Regorafenib 160mg orally daily.

Repeat cycle every 28 days.

OR

First Cycle

Days 1-7: Regorafenib 80mg orally daily

Days 8-14: Regorafenib 120mg orally daily

Days 15-21: Regorafenib 160mg orally daily

Subsequent Cycles:

Days 1-21: Regorafenib 160mg orally daily

Repeat cycle every 4 weeks.

Trifluridine + tipiracil31

Days 1–5 and 8–12: Trifluridine + tipiracil 35mg/m2 up to a maximum dose of 80mg/dose (based on the trifluridine component) orally twice daily.

Repeat cycle every 28 days.

Pembrolizumab32

Day 1: Pembrolizumab 2mg/kg IV

OR

Day 1: Pembrolizumab 200mg IV.

Repeat every 3 weeks.

Nivolumab33

Day 1: Nivolumab 3mg/kg IV

OR

Day 1: Nivolumab 240mg IV.

Repeat every 2 weeks.

Adjuvant Chemotherapy Regimens

Principals of Adjuvant Therapy1

• FOLFOX is superior to 5-FU/leucovorin for patients with stage III colon cancer.

• Capecitabine/oxaliplatin is superior to bolus 5-FU/ leucovorin for patients with stage III colon cancer.

• Capecitabine appears to be equivalent to bolus 5-FU/leucovorin in patients with stage III colon cancer.

• A survival benefit has not been demonstrated for the addition of oxaliplatin to 5-FU/leucovorin in stage II colon cancer. FOLFOX is reasonable for high-risk stage II patients and is not indicated for good- or average-risk patients with stage II colon cancer.

• A benefit for the addition of oxaliplatin to 5-FU/leucovorin in patients age 70 and older has not been proven.

• In patients staged as T1-3, N1 (low-risk stage III), 3 months of CapeOX is non-inferior to 6 months of CapeOX for disease-free survival; non-inferiority of 3 vs 6 months of FOLFOX has not been proven. In patients staged as T4, N1-2 or T any, N2 (high-risk stage III), 3 months of FOLFOX is inferior to 6 months of FOLFOX for disease-free survival, whereas non-inferiority of 3 vs 6 months of CapeOX has not been proven. Grade 3+ neurotoxicity rates are lower for patients who receive 3 months vs 6 months of treatment (3% vs 16% for FOLFOX; 3% vs 9% for CapeOX).

mFOLFOX63,4, 34,a

Day 1: Leucovorin 400mg/m2 IV over 2 hours

Days 1–2: 5-FU 400mg/m2 IV bolus on day 1, then 1,200mg/m2/day × 2 days (total 2,400mg/m2 over 46–48 hours) continuous infusion.

Repeat cycle every 2 weeks.

Capecitabine35

Days 1–14: Capecitabine 1,000-1,250mg/m2 orally twice daily.

Repeat cycle every 3 weeks for 24 weeks.

CapeOx36,37,b

Day 1: Oxaliplatin 130mg/m2 IV over 2 hours

Days 1–14: Capecitabine 1,000mg/m2 orally twice daily.

Repeat cycle every 3 weeks for 24 weeks.

5-FU/leucovorin38,39,a

Leucovorin 500mg/m2 given as a 2-hour infusion and repeated weekly × 6 weeks, plus 5-FU 500mg/m2 given IV bolus 1 hour after the start of leucovorin and repeated weekly × 6 weeks.

Repeat cycle every 8 weeks for 4 cycles.

OR

Simplified biweekly infusional 5-FU/LV (sLV5FU2)

Leucovorin 400mg/m2 IV over 2 hours on day 1, followed by 5-FU bolus 400mg/m2 and then 1,200mg/m2/day × 2 days (total 2,400mg/m2 over 46-48 hours) continuous infusion.

Repeat cycle every 2 weeks.

a Leucovorin 400mg/m2 is the equivalent of levoleucovorin 200mg/m2.

b The majority of safety and efficacy data for this regimen have been developed in Europe, where a capecitabine starting dose of 1,000mg/m2 twice daily for 14 days, repeated every 21 days, is standard. Evidence suggests that North American patients may experience greater toxicity with capecitabine (as well as with other fluoropyrimidines) than European patients, and may require a lower dose of capecitabine.

References

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.2.2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed May 8, 2018.

2. deGramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced rectal cancer. J Clin Oncol. 2000;18:2938-2947.

3. Cheeseman SL, Joel SP, Chester JD, et al. A ‘modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer. 2002;87:393-399.

4. Maindrault-Goebel F, deGramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Ann Oncol. 2000;11:1477-1483.

5. Hochster HS, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol. 2014;25:1172-1178.

6. Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer. 2007;7:91.

7. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as firstline treatment in patients with previously untreated metastatic colorectal ­cancer: the PRIME study. J Clin Oncol. 2010;28:4697-4705.

8. Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5- FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum [abstract]. ASCO Meeting Abstracts 2014;32:LBA3.

9. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-2019.

10. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur J Cancer. 1999;35(9):1343-1347.

11. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25:4779-4786.

12. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomized, open-label, phase 3 trial. Lancet Oncol. 2014.

13. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.

14. Martín-Martorell P, Roselló S, Rodríguez-Braun E, et al. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer. 2008;99:455-458.

15. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706-4713.

16. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. J Clin Oncol. 2012;30:3499-3506.

17. Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomized, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499-508.

18. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670-1676.

19. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306-1315.

20. Haller DG, Rothenberg ML, Wong AO, et al. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol. 2008;26:4544-4550.

21. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Protocol C-03. J Clin Oncol. 1993;11:1879-1887.

22. Jäger E, Heike M, Bernhard H, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. J Clin Oncol. 1996;14:2274-2279.

23. Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an openlabel, randomised phase 3 trial. Lancet Oncol. 2013;14:1077-1085.

24. Cunningham D, Pyrhonen S, James R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. The Lancet. 1998;352:1413-1418.

25. Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003;21:807-814.

26. Van Cutsem E, Tejpar S, Vanbeckevoort D, et al. Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. J Clin Oncol. 2012;30:2861-2868.

27. Kopetz S, McDonough SL, Lenz, H-J, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol. 2017;35(suppl; abstr 3505).

28. Van Custem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapyrefractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-1664.

29. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet. 2013;381:303-312.

30. Bekaii-Saab, TS, Ou F-S, Anderson DM, et al. Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)—An ACCRU Network study. J Clin Oncol. 2018;36(suppl 4S;abstr 611).

31. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer (RECOURSE). N Engl J Med. 2015;372:1909-19.

32. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-2520.

33. Overman MJ, Kopetz S, McDermott RS, et al. Nivolumab {+/-} ipilimumab in treatment of patients with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results [abstract]. ASCO Meeting Abstracts 2016;34:3501.

34. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.

35. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352: 2696-2704.

36. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007;25:102-109.

37. Haller DG, Tabernero J, Maroun J, et al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer. J Clin Oncol. 2011;29:1465-1471. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21383294.

38. Haller DG, Catalano PJ, Macdonald JS Mayer RJ. Phase III study of fluorouracil, leucovorin and levamisole in high risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005:23:8671-8678.

39. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur J Cancer. 1999;35(9):1343-1347.

(Revised 5/2018)

© 2018 Haymarket Media, Inc.


Gastrointestinal Cancer Drug Monographs

Colorectal and Other GI Cancers

AVASTIN CAMPTOSAR CYRAMZA
Doxorubicin HCl Doxorubicin HCl Solution ELOXATIN
ERBITUX Floxuridine Fluorouracil
FUSILEV GLEEVEC HERCEPTIN
Leucovorin LONSURF Mitomycin
NEXAVAR PHOTOFRIN STIVARGA
SUTENT TAXOTERE VECTIBIX
XELODA ZALTRAP

Pancreatic, Thyroid, And Other Endocrine Cancers

ABRAXANE AFINITOR CAPRELSA
COMETRIQ Doxorubicin HCl Doxorubicin HCl Solution
Fluorouracil GEMZAR LENVIMA
LYSODREN Mitomycin NEXAVAR
ONIVYDE SOMATULINE DEPOT SUTENT
TARCEVA THYROGEN ZANOSAR

Data provided by MPR.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs